Samit Hirawat, Bristol Myers Squibb EVP, CMO, Global Drug Development
Bristol Myers jumps into the M&A game with a $4B oncology buyout. And weary biotech analysts couldn't be any happier
Bristol Myers Squibb has nabbed Turning Point Therapeutics in a $4.1 billion buyout deal, just weeks after the biotech posted an upbeat round of positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
